Similar Papers

Paper Title
Journal
Date
Author
Healthcare Resource Utilization and Costs Associated with Obinutuzumab Plus Bendamustine Versus Rituximab Plus Bendamustine for First-Line Treatment of Follicular Lymphoma
Tu My To ... Sheila Shapouri
Blood | VOL. 138
Tu My To, et. al.Tu My To ... Sheila Shapouri
05 Nov 2021
Treatment Patterns and Outcomes Among Patients with Relapsed/Refractory Follicular Lymphoma Treated in Routine Clinical Practice in the US with Three or More Lines of Therapy
Jamie T Ta ... Sheila Shapouri
Blood | VOL. 138
Jamie T Ta, et. al.Jamie T Ta ... Sheila Shapouri
05 Nov 2021
Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study
...
Blood | VOL. 138
, et. al. ...
05 Nov 2021
Real-World Persistence with and Adherence to Emicizumab Prophylaxis in Persons with Hemophilia a: A Secondary Claims Database Analysis
Arash Mahajerin ... Karina Raimundo
Blood | VOL. 136
Arash Mahajerin, et. al.Arash Mahajerin ... Karina Raimundo
05 Nov 2020
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Advances in RNA editing in hematopoiesis and associated malignancies.
Shuangshuang Pu ... Hui Cheng
Blood | VOL. -
Shuangshuang Pu, et. al.Shuangshuang Pu ... Hui Cheng
27 Jan 2025
Protection of β2GPI-Deficient Mice from Thrombosis Reflects a Defect in PAR3-facilitated Platelet Activation.
Paresh P Kulkarni ... Keith R Mccrae
Blood | VOL. -
Paresh P Kulkarni, et. al.Paresh P Kulkarni ... Keith R Mccrae
27 Jan 2025
Babesiosis and Sickle Red blood Cells: Loss of Deformability, Heightened Osmotic fragility, and Hypervesiculation.
Divya Beri ... Cheryl A Lobo
Blood | VOL. -
Divya Beri, et. al.Divya Beri ... Cheryl A Lobo
27 Jan 2025
Platelet activation and signaling in thrombus formation.
Frauke Swieringa ... Alice Assinger
Blood | VOL. -
Frauke Swieringa, et. al.Frauke Swieringa ... Alice Assinger
27 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.